In Reply We thank Calabrò et al for their very thoughtful letter in response to our study.1 They have correctly noted that the estimates for those requiring proprotein convertase subtilisin/kexin type 9 inhibitors would be further modified by incorporating realistic assumptions on patients unable to tolerate a statin or uptitration of a statin. We have done these analyses and presented preliminary data at the American College of Cardiology Scientific Sessions this year,2 and we plan to submit an article with a more complete analysis soon.